An observational study in Autism Spectrum Disorder, Siblings and Neurodevelopmental Disorders, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by University Hospital, Montpellier · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier — 5 open to participants now, 6 under way, none of them phase 3. Autism Spectrum Disorder · University Hospital, Montpellier.
Among the 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier, this one is one of 3 that started in 2023, is one of 6 observational ones, and was the 9th registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →5 of the 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 1–16 · Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 2–5
University Hospital, Montpellier · Sites in France
Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 6–16
By country, each count listing its studies:
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 2 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 384 is above the median of 103 across 323 observational studies indexed under Autism Spectrum Disorder.
Median enrollment 62 across the 6 interventional studies, 752 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
1 of the studies in Autism Spectrum Disorder by University Hospital, Montpellier that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05512637University Hospital, MontpellierScreening for Neurodevelopmental Disorders in Siblings of Children With Autism Diagnosed in Tertiary Centers | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study, a selective and multi-stages screening for neurodevelopmental disorders (NDD) in siblings of children with a confirmed ASD is done. The main aims are to estimate the prevalence of NDD among siblings and to evaluate the feasibility and acceptability of a standardized screening procedure.
Although NDD are frequent among siblings of children with ASD, their developmental screening is not yet sufficiently organized in routine practice. The needs and the characteristics of these siblings have yet to be better understood in order to define their developmental surveillance.
The expected number of children is 384 children (142 with NDD and 242 without NDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Step 1 - Screening: the targeted sample is the siblings of the autistic children, these siblings being at risk of neurodevelopmental disorders. Step 2 - Clinical interview: All the children with a positive screening.
Diagnostic Test: Step 1 - Screening ; Step 2 - Clinical interview
Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview. Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process.
Percentage of family participation
Families' participation rate and, among participants, number of children with a NDD diagnosis at the end of the screening study.
Time frame: 12 months
Sensibility, specificity, positive predictive values (PPV) and negative predictive values (NPV) of the screening procedure
Time frame: 12 months
Percentage of satisfied parents
Estimate the level of satisfaction of parents who participated in the screening with the parental satisfaction score via the Visual Analog Scale (VAS). VAS is a scale from 0 (not at all satisfied) to 100 (very satisfied)
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.
Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 36 months is below that.
Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →